{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:31:14Z","timestamp":1789029074948,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-8722-7-11","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T16:09:41Z","timestamp":1390493381000},"source":"Crossref","is-referenced-by-count":193,"title":["Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses"],"prefix":"10.1186","volume":"7","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Padmanabhan Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wolfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Balser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"issue":"25","key":"444_CR1","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K: Peripheral T-cell lymphoma. Blood. 2011, 117 (25): 6756-6767. 10.1182\/blood-2010-05-231548.","journal-title":"Blood"},{"issue":"25","key":"444_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008, 26 (25): 4124-4130.","journal-title":"J Clin Oncol"},{"issue":"5","key":"444_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/CCO.0b013e3282ce6f8f","volume":"19","author":"SM Horwitz","year":"2007","unstructured":"Horwitz SM: Management of peripheral T-cell non-Hodgkin's lymphoma. Curr Opin Oncol. 2007, 19 (5): 438-443. 10.1097\/CCO.0b013e3282ce6f8f.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"444_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1008200307625","volume":"8","author":"S Ascani","year":"1997","unstructured":"Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, de Vivo A, Piccioli M, Fraternali Orcioni G, Pieri F, Goldoni A: Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol. 1997, 8 (6): 583-592. 10.1023\/A:1008200307625.","journal-title":"Ann Oncol"},{"issue":"7","key":"444_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998, 9 (7): 717-720. 10.1023\/A:1008265532487.","journal-title":"Ann Oncol"},{"issue":"7\u20138","key":"444_CR6","first-page":"396","volume":"43","author":"S Nakamura","year":"1993","unstructured":"Nakamura S, Koshikawa T, Koike K, Kitoh K, Suzuki H, Oyama A, Motoori T, Kojima M, Ogura M, Kurita S: Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn. 1993, 43 (7\u20138): 396-412.","journal-title":"Acta Pathol Jpn"},{"issue":"1","key":"444_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, M\u00fcller-Hermelink HK: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002, 13 (1): 140-149. 10.1093\/annonc\/mdf033.","journal-title":"Ann Oncol"},{"key":"444_CR8","unstructured":"NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. 2013, 2"},{"key":"444_CR9","volume-title":"Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment [abstract 1614]","author":"FM Foss","year":"2012","unstructured":"Foss FM, Carson KR, Pinter-Brown L, Horwitz SM, Rosen ST, Pro B, Federico M, Gisselbrecht C, Hsi ED: Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment [abstract 1614]. 2012, Presented at: ASH Annual Meeting and Exposition"},{"key":"444_CR10","volume-title":"Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort [abstract 2728]","author":"AM Evens","year":"2012","unstructured":"Evens AM, Feldman T, Kroll A, Muffly LS, Winer E, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A: Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort [abstract 2728]. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"320624","DOI":"10.1155\/2010\/320624","volume":"2010","author":"P Reimer","year":"2010","unstructured":"Reimer P: Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol. 2010, 2010: 320624-","journal-title":"Adv Hematol"},{"issue":"12","key":"444_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/bmt.2008.332","volume":"42","author":"A Gutierrez","year":"2008","unstructured":"Gutierrez A, Caballero MD, Perez-Manga G, Rodriguez J: Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant. 2008, 42 (12): 773-781. 10.1038\/bmt.2008.332.","journal-title":"Bone Marrow Transplant"},{"key":"444_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186\/1756-8722-3-5.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"444_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5 (9): 769-784. 10.1038\/nrd2133.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"444_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nchembio.313","volume":"6","author":"JE Bradner","year":"2010","unstructured":"Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R: Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010, 6 (3): 238-243. 10.1038\/nchembio.313.","journal-title":"Nat Chem Biol"},{"key":"444_CR16","unstructured":"ISTODAX (romidepsin) [package insert]. 2013, Summit, NJ: Celgene Corporation"},{"issue":"6","key":"444_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M: Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012, 30 (6): 631-636. 10.1200\/JCO.2011.37.4223.","journal-title":"J Clin Oncol"},{"key":"444_CR18","unstructured":"FOLOTYN (pralatrexate) [package insert]: 2009, Westminster, CO: Allos Therapeutics, Inc"},{"key":"444_CR19","unstructured":"Adcetris (brentuximab vedotin) [package insert]: 2011, Bothell, WA: Seattle Genetics, Inc"},{"issue":"9","key":"444_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011, 29 (9): 1182-1189. 10.1200\/JCO.2010.29.9024.","journal-title":"J Clin Oncol"},{"issue":"18","key":"444_CR21","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012, 30 (18): 2190-2196. 10.1200\/JCO.2011.38.0402.","journal-title":"J Clin Oncol"},{"key":"444_CR22","volume-title":"Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract 2745","author":"B Pro","year":"2012","unstructured":"Pro B, Advani RH, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous JV, Ramchandren R, Fanale MA, Connors JM: Long-term remissions observed in an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract 2745. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR23","volume-title":"A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results [abstract 2746]","author":"ED Jacobsen","year":"2012","unstructured":"Jacobsen ED, Advani RH, Oki Y, Sharman J, Horwitz SM, Forero-Torres A, O'Connor OA, Shustov AR, Siddiqi T, Grove LE: A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results [abstract 2746]. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR24","volume-title":"Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin","author":"CJ Godfrey","year":"2011","unstructured":"Godfrey CJ, Cabell CH, Balser B, Wolfson J, Nichols J, Burris HA: Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin. 2011, Presented at: ASH Annual Meeting and Exposition, December 10\u201313"},{"key":"444_CR25","volume-title":"Trends in incidence and outcome in T-cell lymphoma since 1992: A SEER database analysis [abstract 4264]","author":"AM Petrich","year":"2012","unstructured":"Petrich AM, Helenowski I, Galamaga RW, Nabhan C: Trends in incidence and outcome in T-cell lymphoma since 1992: A SEER database analysis [abstract 4264]. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR26","first-page":"393","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM: Improving outcomes for patients with large B-cell lymphoma. CA Cancer J Clin. 2010, 60: 393-408.","journal-title":"CA Cancer J Clin"},{"key":"444_CR27","volume-title":"A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the ro-CHOP study [abstract 1617]","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Casasnovas R, Ghesquieres H, Morschhauser F, Tilly H, Thieblemont C, Ribrag V, Coiffer B: A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the ro-CHOP study [abstract 1617]. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR28","unstructured":"Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma. \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01796002\n                    \n                  . Accessed March 4, 2013"},{"key":"444_CR29","volume-title":"Combination chemotherapy and pralatrexate as first-line therapy in treating patients with non-Hodgkin lymphoma","author":"MA Fanale","year":"2012","unstructured":"Fanale MA, Shustov AR, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Kennedy DA, Horwitz SM: Combination chemotherapy and pralatrexate as first-line therapy in treating patients with non-Hodgkin lymphoma. 2012, Presented at: ASH Annual Meeting and Exposition, December 8\u201311"},{"key":"444_CR30","unstructured":"Combination chemotherapy and pralatrexate as first-line therapy in treating patients with non-Hodgkin lymphoma. \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01336933\n                    \n                  . Accessed December 21, 2012"},{"key":"444_CR31","unstructured":"Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients. \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01420679\n                    \n                  . Accessed March 4, 2013"},{"issue":"4","key":"444_CR32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, NCI sponsored International Working Group: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999, 17 (4): 1244-","journal-title":"J Clin Oncol"},{"issue":"12","key":"444_CR33","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"RL Piekarz","year":"2006","unstructured":"Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006, 12 (12): 3762-3773. 10.1158\/1078-0432.CCR-05-2095.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-7-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-7-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-7-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:32:11Z","timestamp":1548196331000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-7-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-7-11","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]},"article-number":"11"}}